{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_52601"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_52601","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Essays in Health Economics","abstract":"Thesis (Ph.D.)--Michigan State University. Economics - Doctor of Philosophy, 2025","abstract_html":"Thesis (Ph.D.)--Michigan State University. Economics - Doctor of Philosophy, 2025","abstract_has_math":false,"creators":["Roberts, Meaghan Higgins"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Dickert-Conlin, Stacy","Conlin, Mike","Loveridge, Scott","Kim, Paul"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T18:59:09Z","subjects":["Economics"],"languages":["eng"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52601","local:Roberts_grad.msu_0128D_21564"],"render_values":[{"text":"etd:52601","href":null,"code":true},{"text":"local:Roberts_grad.msu_0128D_21564","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/jafe-t243","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/jafe-t243","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_52601","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dickert-Conlin, Stacy","Conlin, Mike","Loveridge, Scott","Kim, Paul"]},{"key":"dc:creator","label":"Author","values":["Roberts, Meaghan Higgins"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic dissertations"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Economics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52601","local:Roberts_grad.msu_0128D_21564","https://doi.org/doi:10.25335/jafe-t243"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (Ph.D.)--Michigan State University. Economics - Doctor of Philosophy, 2025","This collection of essays studies the diverse consequences of state opioid prescribing policy. In response to the epidemic of misuse and overdose death from prescription opioid painkillers, states enacted policies to reduce excessive prescribing. One policy, a Must-Access Prescription Drug Monitoring Program (MA-PDMP), requires physicians to check a state-run database prior to prescribing opioids, adding a time-consuming task, or hassle cost, to the prescription decision. In Chapter 1, I estimate the impact of MA-PDMP-related hassle costs on prescribing of opioids as well as substitution to alternative therapies for pain. Using rich ACA Exchange Plan medical and pharmaceutical claims data from 2016-2019, I find that physicians who face a high hassle cost of prescribing opioids, relative to those who do not, reduce opioid prescribing by 6.2% and increase prescribing of unproven therapies that are not FDA-approved to treat pain by 12.7%. Because MA-PDMPs alter physicians’ prescribing environment and reduce the size of the market for opioids, opioid manufacturers may adjust their marketing strategies following policy implementation. In Chapter 2, I use rich data on pharmaceutical firm marketing from the Centers for Medicare and Medicaid Services (CMS) Open Payments database to examine the effect of MA-PDMPs on county-level, opioid-related marketing to physicians. Given geographic economies of scale in direct marketing, I also assess for marketing spillovers into bordering counties in states without an MA-PDMP. Using an event study model and exploiting the staggered adoption of MA-PDMPs over 2014-2019, I find no effect of MA-PDMP implementation on county-level opioid-related marketing to physicians, both within MA-PDMP states and across state borders.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf","1 online resource (126 p.) : ill."]},{"key":"dc:title","label":"Title","values":["Essays in Health Economics"]}]}],"canonical_facts":{"dc:contributor":["Dickert-Conlin, Stacy","Conlin, Mike","Loveridge, Scott","Kim, Paul"],"dc:creator":["Roberts, Meaghan Higgins"],"dc:date":["2025"],"dc:description":["Thesis (Ph.D.)--Michigan State University. Economics - Doctor of Philosophy, 2025","This collection of essays studies the diverse consequences of state opioid prescribing policy. In response to the epidemic of misuse and overdose death from prescription opioid painkillers, states enacted policies to reduce excessive prescribing. One policy, a Must-Access Prescription Drug Monitoring Program (MA-PDMP), requires physicians to check a state-run database prior to prescribing opioids, adding a time-consuming task, or hassle cost, to the prescription decision. In Chapter 1, I estimate the impact of MA-PDMP-related hassle costs on prescribing of opioids as well as substitution to alternative therapies for pain. Using rich ACA Exchange Plan medical and pharmaceutical claims data from 2016-2019, I find that physicians who face a high hassle cost of prescribing opioids, relative to those who do not, reduce opioid prescribing by 6.2% and increase prescribing of unproven therapies that are not FDA-approved to treat pain by 12.7%. Because MA-PDMPs alter physicians’ prescribing environment and reduce the size of the market for opioids, opioid manufacturers may adjust their marketing strategies following policy implementation. In Chapter 2, I use rich data on pharmaceutical firm marketing from the Centers for Medicare and Medicaid Services (CMS) Open Payments database to examine the effect of MA-PDMPs on county-level, opioid-related marketing to physicians. Given geographic economies of scale in direct marketing, I also assess for marketing spillovers into bordering counties in states without an MA-PDMP. Using an event study model and exploiting the staggered adoption of MA-PDMPs over 2014-2019, I find no effect of MA-PDMP implementation on county-level opioid-related marketing to physicians, both within MA-PDMP states and across state borders.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."],"dc:format":["application/pdf","1 online resource (126 p.) : ill."],"dc:identifier":["etd:52601","local:Roberts_grad.msu_0128D_21564","https://doi.org/doi:10.25335/jafe-t243"],"dc:language":["eng"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Economics"],"dc:title":["Essays in Health Economics"],"dc:type":["text","Electronic dissertations"]},"updated_at":"2026-11-18T18:59:09Z"}